Design of SaCas9-HF for In Vivo Gene Therapy

Kartikeya Tiwari; Ritesh Kumar; Prakash Saudagar

doi:10.1007/978-1-0716-2716-7_12

Design of SaCas9-HF for In Vivo Gene Therapy

Methods Mol Biol. 2023:2575:261-268. doi: 10.1007/978-1-0716-2716-7_12.

Authors

Kartikeya Tiwari¹, Ritesh Kumar², Prakash Saudagar³

Affiliations

¹ School of Medicine, Ophthalmology, Visual and Anatomical Sciences, Wayne State University, Detroit, MI, USA.
² Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.
³ Department of Biotechnology, National Institute of Technology, Warangal, Telangana, India. ps@nitw.ac.in.

PMID: 36301479
DOI: 10.1007/978-1-0716-2716-7_12

Abstract

Genome alteration results in several diseases for which therapeutics are limited. Gene editing provides a strong and potential alternative for the treatment of rare and genetic diseases. CRISPR-Cas9-based system is now being envisaged as a potential tool for the cure of genetic diseases. The RNA-guided nuclease, SaCas9 enzyme, along with its HF versions is widely employed for in vivo gene editing because of its small size and high efficiency. The current work summarizes the widely used and improved methods for in vivo manipulation of genes. The potential of CRISPR-Cas9-based systems can be harnessed to treat genetic diseases and holds great promise for therapeutic interventions in gene therapy. The in vivo gene editing poses a caveat in the form of delivery systems, the tissue in question, and several other factors. This work describes the methods which have been optimized to offer high efficiency, delivery, and gene editing in vivo.

Keywords: CRISPR-Cas9; In vivo gene editing; SaCas9 HF.

MeSH terms

CRISPR-Cas Systems* / genetics
Endonucleases / genetics
Gene Editing / methods
Genetic Therapy
Staphylococcus aureus* / metabolism

Substances

Endonucleases